Creating bottom-up RNA transfer vehicles from synthetic protein assemblies
Open Access
- 2 September 2026
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 658 (8136) , 805-813
Abstract
Evolution guides biological systems to populate ecological niches, with viruses among the most successful examples of this principle. Viruses evolved over billions of years to efficiently transfer genetic information. Although viruses are highly diverse, most have converged towards remarkable similarity in the size and shape of their capsids 1,2 . By contrast, generative models for protein design enable the creation of protein architectures that are absent from nature 3–5 . Here we investigate whether protein assemblies designed by artificial intelligence can be functionalized to construct nucleic acid transport vehicles that are independent of evolutionary trajectories. By combining natural protein domains with synthetic protein assemblies, we create more than 100 bottom-up RNA transfer vehicles with unique sizes and shapes. These vehicles surpass the RNA transfer efficiency of widely used delivery vehicles by several orders of magnitude. In addition, we demonstrate that their tropism can be programmed by incorporation of computationally designed peptide binders and use them to deliver therapeutically relevant cargo RNAs into a wide range of cellular models. We show the in vivo biodistribution of one of these vehicles in a mouse at near-single-cell resolution, confirm its safety, and use it to perform a gene-editing treatment strategy for Duchenne muscular dystrophy in patient-derived cells and a pig. Our work demonstrates how proteins created by generative artificial intelligence can be harnessed for the rational engineering of RNA transport systems with the desired properties by overcoming the limitations of natural protein diversity.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- A new age in protein design empowered by deep learningCell Systems, 2023
- Lethal immunotoxicity in high-dose systemic AAV therapyMolecular Therapy, 2023
- Engineering RNA export for measurement and manipulation of living cellsCell, 2023
- Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV ProvirusMolecular Therapy, 2019
- Designed proteins induce the formation of nanocage-containing extracellular vesiclesNature, 2016
- Eteplirsen for the treatment of Duchenne muscular dystrophyAnnals of Neurology, 2013
- Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamicsNature, 2013
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005
- Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domainCell, 1995